Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896951298> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2896951298 endingPage "S65" @default.
- W2896951298 startingPage "S65" @default.
- W2896951298 abstract "To evaluate the feasibility, safety and short-term efficacy of preoperative capecitabine and simultaneous integrated boost IMRT-based, followed by a cycle of neoadjuvant capecitabine in patients with locally advanced rectal cancer(LARC). Between March 2015 and July 2016, a total of 43 patients with resectable stage II or III rectal cancer received capecitabine (825 mg/m2, bid d1-5 weekly) and SIB-IMRT delivering 58.75 Gy (2.35Gy/fraction) to the gross tumor and regional metastatic lymph nodes while simultaneously delivering 50Gy (2.0 Gy/fraction) to the areas at high risk for harboring microscopic disease. One cycle of capecitabine (1250 mg/m2, bid d1-14) was given one week after the completion of neoadjuvant chemoradiation (nCRT), and TME was scheduled 6 to 8 weeks after the completion of nCRT. The primary endpoint included ypCR. Secondary endpoints included acute toxicity, tumor downstaging, surgical morbidity, R0 resection, postoperative complications, sphincter preservation rate, LR, OS, and DFS. A total of 43 patients completed chemoradiation as the protocol schedule and 40 received surgical resection. 16 (40%) patients had no residual tumor in the surgical specimen. Downstaging of the primary tumor or lymph nodes was observed in 39 (97.5%) patients. Most of the adverse reactions were grade 1/2, Grade 3 diarrhea and radiation dermatitis toxicities were evaluated in two (4.7%) and three cases (7.0%). No grade 4-5 toxicities were observed. Thirty patients underwent sphincter-saving surgery. Postoperative complications included 1 case of ureteral injury and 1 case of intestinal obstruction, no death in perioperative period. Three patients who refused surgery after chemoradiation therapy were excluded from the analysis, included one patient delayed surgery due to anal edema. The 1-year estimated overall survival and disease-free survival rates were 100 and 100% respectively, and no local relapse was found. The pattern of preoperative SIB-IMRT plus concurrent capecitabine, followed by one cycle neoadjuvant capecitabine is a safe, well-tolerated treatment, gained a good pCR for patients with locally advanced rectal cancer, and the short-term outcomes could be promising." @default.
- W2896951298 created "2018-10-26" @default.
- W2896951298 creator A5007453059 @default.
- W2896951298 creator A5012655191 @default.
- W2896951298 creator A5025190969 @default.
- W2896951298 creator A5035423427 @default.
- W2896951298 creator A5044461669 @default.
- W2896951298 creator A5051014138 @default.
- W2896951298 creator A5062163968 @default.
- W2896951298 creator A5064295764 @default.
- W2896951298 creator A5064778313 @default.
- W2896951298 creator A5078581542 @default.
- W2896951298 creator A5079948316 @default.
- W2896951298 date "2018-11-01" @default.
- W2896951298 modified "2023-09-26" @default.
- W2896951298 title "Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study" @default.
- W2896951298 doi "https://doi.org/10.1016/j.ijrobp.2018.06.180" @default.
- W2896951298 hasPublicationYear "2018" @default.
- W2896951298 type Work @default.
- W2896951298 sameAs 2896951298 @default.
- W2896951298 citedByCount "1" @default.
- W2896951298 countsByYear W28969512982021 @default.
- W2896951298 crossrefType "journal-article" @default.
- W2896951298 hasAuthorship W2896951298A5007453059 @default.
- W2896951298 hasAuthorship W2896951298A5012655191 @default.
- W2896951298 hasAuthorship W2896951298A5025190969 @default.
- W2896951298 hasAuthorship W2896951298A5035423427 @default.
- W2896951298 hasAuthorship W2896951298A5044461669 @default.
- W2896951298 hasAuthorship W2896951298A5051014138 @default.
- W2896951298 hasAuthorship W2896951298A5062163968 @default.
- W2896951298 hasAuthorship W2896951298A5064295764 @default.
- W2896951298 hasAuthorship W2896951298A5064778313 @default.
- W2896951298 hasAuthorship W2896951298A5078581542 @default.
- W2896951298 hasAuthorship W2896951298A5079948316 @default.
- W2896951298 hasConcept C121608353 @default.
- W2896951298 hasConcept C126322002 @default.
- W2896951298 hasConcept C126838900 @default.
- W2896951298 hasConcept C141071460 @default.
- W2896951298 hasConcept C146357865 @default.
- W2896951298 hasConcept C151730666 @default.
- W2896951298 hasConcept C168563851 @default.
- W2896951298 hasConcept C197934379 @default.
- W2896951298 hasConcept C203092338 @default.
- W2896951298 hasConcept C2777909004 @default.
- W2896951298 hasConcept C2778292576 @default.
- W2896951298 hasConcept C2779013556 @default.
- W2896951298 hasConcept C2780283643 @default.
- W2896951298 hasConcept C509974204 @default.
- W2896951298 hasConcept C526805850 @default.
- W2896951298 hasConcept C530470458 @default.
- W2896951298 hasConcept C71924100 @default.
- W2896951298 hasConcept C86803240 @default.
- W2896951298 hasConceptScore W2896951298C121608353 @default.
- W2896951298 hasConceptScore W2896951298C126322002 @default.
- W2896951298 hasConceptScore W2896951298C126838900 @default.
- W2896951298 hasConceptScore W2896951298C141071460 @default.
- W2896951298 hasConceptScore W2896951298C146357865 @default.
- W2896951298 hasConceptScore W2896951298C151730666 @default.
- W2896951298 hasConceptScore W2896951298C168563851 @default.
- W2896951298 hasConceptScore W2896951298C197934379 @default.
- W2896951298 hasConceptScore W2896951298C203092338 @default.
- W2896951298 hasConceptScore W2896951298C2777909004 @default.
- W2896951298 hasConceptScore W2896951298C2778292576 @default.
- W2896951298 hasConceptScore W2896951298C2779013556 @default.
- W2896951298 hasConceptScore W2896951298C2780283643 @default.
- W2896951298 hasConceptScore W2896951298C509974204 @default.
- W2896951298 hasConceptScore W2896951298C526805850 @default.
- W2896951298 hasConceptScore W2896951298C530470458 @default.
- W2896951298 hasConceptScore W2896951298C71924100 @default.
- W2896951298 hasConceptScore W2896951298C86803240 @default.
- W2896951298 hasIssue "3" @default.
- W2896951298 hasLocation W28969512981 @default.
- W2896951298 hasOpenAccess W2896951298 @default.
- W2896951298 hasPrimaryLocation W28969512981 @default.
- W2896951298 hasRelatedWork W1971434702 @default.
- W2896951298 hasRelatedWork W2016170717 @default.
- W2896951298 hasRelatedWork W2032042555 @default.
- W2896951298 hasRelatedWork W2117105709 @default.
- W2896951298 hasRelatedWork W2416699593 @default.
- W2896951298 hasRelatedWork W2761337811 @default.
- W2896951298 hasRelatedWork W3032158305 @default.
- W2896951298 hasRelatedWork W4225255701 @default.
- W2896951298 hasRelatedWork W4306253774 @default.
- W2896951298 hasRelatedWork W4317567212 @default.
- W2896951298 hasVolume "102" @default.
- W2896951298 isParatext "false" @default.
- W2896951298 isRetracted "false" @default.
- W2896951298 magId "2896951298" @default.
- W2896951298 workType "article" @default.